Skip to main content
Fig. 2 | Arthritis Research & Therapy

Fig. 2

From: Preferable outcome of Janus kinase inhibitors for a group of difficult-to-treat rheumatoid arthritis patients: from the FIRST Registry

Fig. 2

Patterns of the treatment switches in D2T RA cases. Sankey diagram of the patients who participated in the FIRST Registry from August 2013 to January 2021 (N = 2176) A coloured by treatment type and B coloured by D2T RA. D2T RA, difficult-to-treat rheumatoid arthritis; TNFi, tumour necrosis factor inhibitor; IL-6Ri, interleukin-6 receptor inhibitor; CTLA4-Ig, cytotoxic T-lymphocyte-associated antigen-4 immunoglobulin; JAKi, Janus kinase inhibitor

Back to article page